Systemic sclerosis therapy options mature past hematopoietic stem cell transplant
Tocilizumab and nintedanib in SSc-ILD, anifrolumab pivotal data, and emerging mechanism-targeted programs are reshaping systemic sclerosis management.
Systemic sclerosis (scleroderma) has been a no-disease-modifying-therapy category for years, with hematopoietic stem cell transplant in selected severe cases. Tocilizumab (IL-6 receptor antagonist) carries SSc-ILD approval, nintedanib has SSc-ILD approval as antifibrotic therapy, anifrolumab (anti-type-I-interferon) is reading out in scleroderma, and emerging mechanism programs (anti-fibroblast, autotaxin pathway, novel B-cell-targeted) are in late-stage trials. The category is acquiring a real disease-modifying therapy frame.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Key sources
Related
- ExplainedWhat is lupus nephritis?
- SnapshotLupus nephritis therapy reference (2026)